Slide 1: Accelerating on the data-driven Autobahn to Cures
Accelerating on the data- driven Autobahn to Cures Evotec SE, First quarter 2021 results, 11 May 2021
Slide 2: Cautionary statement regarding forward-looking statements
Cautionary statement regarding forward-looking statements Information set forth in this presentation contains forward-looking statements, which involve a number of risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, which are often indicat
Slide 3: Welcome – The Management Team
Welcome The Management Team Werner Lanthaler1) Enno Spillner1) Craig Johnstone Cord Dohrmann CEO CFO COO CSO PAGE 2 1) On the call for the first quarter 2021
Slide 4: Agenda
Agenda Highlights Financial performance Q1 2021 Scientific and operational performance Q1 2021 Outlook and Guidance 2021 PAGE 3
Slide 5: Successful start with multiple new and extended partnerships
Successful start with multiple new and extended partnerships Q1 2021 – Highlights Continued strong performance despite COVID-19 pandemic New INDiGO and CMC collaborations Extended targeted protein degradation partnership with Bristol Myers Squibb New iPSC multi-year partnership with the Medi
Slide 6: Record like-for-like growth in base business; guidance confirmed
Record like-for-like growth in base business Financials Q1 2021 & FY 2021 guidance Improving momentum Guidance confirmed Group revenues up 11% Very good top-line growth expected (€ 133.1 m vs. Q1 2020: € 119.4 m) Total Group revenues € 550-570 m (2020: € 500.9 m) Like-for-like growth of Grou
Slide 7: Action Plan 2025 – The data-driven R&D Autobahn to Cures
Action Plan 2025 – The data-driven R&D Autobahn to Cures Our strategic frameworks 2025 2021 2018 2012 Action Plan 2025 2009 Leadership in data, science, Action Plan 2022 multi-modality & access Action Plan 2016 Aspire global leadership Action Plan 2012 Build Innovation seeds Restructure for growth P
Slide 8: Action Plans deliver significant value – “… just at the beginning”
Action Plans deliver significant value – “… just at the beginning” Action Plans in numbers 2025 2021 2018 2012 Action Plan 2025 2009 Leadership in data, science, Action Plan 2022 multi-modality & access Action Plan 2016 Aspire global leadership Action Plan 2012 Build Innovation seeds Restructure for
Slide 9: The power of data & science to deliver enhanced speed, lower cost & predictive efficacy
The power of data & science to deliver enhanced speed, lower cost & predictive efficacy Eight building blocks to improve innovation & value PAGE 8
Slide 10: We offer what the industry truly needs
We offer what the industry truly needs Key growth drivers for high-impact and high-value business R&D efficiency From high quality stand-alone EVOequity & EVOroyalty platforms1) services to EVOiR&D AI/ML & Precision From molecular platforms via iPSCs medicine platforms to EVOpanOmics & EVOpanHunter
Slide 11: Clearly defined, highest quality work drives base business
Clearly defined, highest quality work drives base business Capabilities & expertise overview Industry needs Capabilities & expertise create multimodality & data-driven R&D Autobahn for growth R&D efficiency platforms1) Target ID & Hit Sample DMPK & Research Bio In vitro In vivo Biomarker Integrated
Slide 12: Agenda
Agenda Highlights Financial performance Q1 2021 Scientific and operational performance Q1 2021 Outlook and Guidance 2021 PAGE 11
Slide 13: Very strong like-for-like growth – On track for 2021 goals
Very strong like-for-like growth – On track for 2021 goals Condensed income statement Q1 2021 in EUR m1) Q1 2021 Q1 2020 % vs. 2020 Total fx adj. Group revenue growth Revenues from contracts with customers 133.1 119.4 11% 17% (26%, adjusted for portfolio & fx) R&D as well as SG&A expenses up - G
Slide 14: Dynamic organic growth in base revenues
Dynamic organic growth in base revenues Revenues & Gross margin overview Revenues from contracts Gross margin Growth across all business lines, with customers (in € m) (in %) despite Milestones, upfronts and licences Margin excl. milestones, upfronts and licences and amortisation anticipated end
Slide 15: Integrated offering drives strong growth in both segments
Integrated offering drives strong growth in both segments Segment information Q1 2021 – Evotec SE and subsidiaries in EUR m1) Inter- EVT EVT segment Evotec EVT Execute: 16% revenue growth Execute Innovate elimination Group including inter-segment revenues implies accelerating demand for Revenues 1
Slide 16: Base business at record growth
Base business at record growth Revenue bridge Q1 2020 – Q1 2021 in EUR m 133.2 Reported 11% growth of Group 28.4 6.0 revenues 119.4 8.6 110.8 Comparable base for the last time adjusted for end of Sanofi payment (Contract ended on 31 March 2020: € (8.6) m in Q1 2020 fx effect: € (6.0) m (-5%)
Slide 17: EBITDA with organic double-digit growth
EBITDA with organic double-digit growth EBITDA bridge Q1 2020 – Q1 2021 in EUR m 30.0 Reported decline of 30% affected from end of Sanofi payment for the last time 8.6 Comparable base adjusted 21.4 3.3 3.6 21.1 accordingly fx effect: € (3.6) m (-12%) Like-for-like EBITDA increase of € 3.3 m
Slide 18: Strong balance sheet and cash position
Strong balance sheet and cash position Balance sheet – 31 Mar. 2021 versus 31 December 2020 Balance sheet total Equity ratio Equity ratio > around 50% in € m in % Leverage ratio of 0.6x EBITDA, providing flexibility to make use of strengthened balance sheet for 1,462.9 1,580.7 49.4 50.2 ambitiou
Slide 19: Agenda
Agenda Highlights Financial performance Q1 2021 Scientific and operational performance Q1 2021 Outlook and Guidance 2021 PAGE 18
Slide 20: The iceberg of EVT Innovate product opportunities
The iceberg of EVT Innovate product opportunities In total > 200 projects with financial upside within “EVOroyalty” Global Neuroscience & Pain Oncology Metabolic Diseases Inflammation & Immunology* Virology Anti-bacterial Health Ph3 Insomnia Carrick Ph2 CC - P2X3 NP– P2X3 OAB–P2X3 Breast cancer Endo
Slide 21: Molecular patient data bases are re-defining health and disease
Molecular patient data bases are re-defining health and disease The foundation of precision medicine Tuber- Liver culosis disease Multiple rare Infectious diseases diseases Autoimmune CNS disease Kidney diseases Fibrosis PATIENT DATABASES WITH CLINICAL AND MOLECULAR PROFILES Lung & Multiple cancers
Slide 22: Molecular patient database grows in depth and breadth
Molecular patient database grows in depth and breadth Example Kidney/Liver: Value of data grows exponentially with access to further biobanks Understanding of disease relevance (CKD) Longitudinal biosamples for 5,000 CKD patients Healthy tissue & expansion into liver > 1,000 patients Biosamples from
Slide 23: Rapid development of efficient antibodies
Rapid development of efficient antibodies Just – Evotec Biologics Manufacturing Discovery High-Speed Autobahn network Library Abacus PAGE 22
Slide 24: Just – Evotec Biologics on track for commercial manufacturing
Just – Evotec Biologics on track for commercial manufacturing J.POD® facilities and highlights J.POD® 1 US facility J.POD® 1 US – construction work making considerable progress Alliance with Department of Defense for anti-SARS-Cov2 antibodies fully on track, multiple other new partnerships initi
Slide 25: BRIDGEs bring multiple future investment options
BRIDGEs bring multiple future investment options Creating long-term optionality with efficient translation Basic Applied Technology Development Product Commercialisation Market Entry & Research Research and Demonstration and Market Development Market Volume Public Market Funding Level Pension Plan P
Slide 26: Very good progress within Evotec’s equity portfolio
Very good progress within Evotec’s equity portfolio Equity participations for co-owned pipeline At equity investments (share ≥ 20% or significant influence) Joint Venture Equity participation Spin-off Equity participation Spin-off Equity participation Equity participation Equity participation Joint
Slide 27: Agenda
Agenda Highlights Financial performance Q1 2021 Scientific and operational performance Q1 2021 Outlook and Guidance 2021 PAGE 26
Slide 28: Keeping the promise – ESG & Sustainability
Keeping the promise ESG & Sustainability – Measures taken in Q1 2021 First steps to reduce emissions Sourcing of 100% renewable energy since January 2021 at all German sites Organisational alignments Group-wide inclusion of ESG topics in personal 2021 targets of all employees Implementatio
Slide 29: Strong year ahead – Guidance 2021
Strong year ahead Guidance 2021 Very good top-line growth expected Assumption based on current orders, prospective milestone payments Total Group revenues € 550-570 m (€ 565-585 m at constant exchange rates1)) Strong EBITDA – despite massive investments Regardless of COVID-19, increasing expen
Slide 30: Our mid-term aspirations are “…just the beginning”
Our mid-term aspirations are “…just the beginning” 2020-2025e Key Performance Indicator goals Revenues Adjusted EBITDA1) in € m in € m >100% ≥180% 500.9 >1,000 106.6 ≥300 Unpartnered R&D Co-owned projects2) in € m >100% >100% 46.4 >100 118 >250 PAGE 29 1) before significant royalties 2) incl. Equity
Slide 31: Strong short-term news flow to be continued
Strong short-term news flow to be continued Overview EVT Execute New integrated service alliances in drug discovery & development EVT Innovate New clinical initiations and progress of co-owned pipeline New co-owned partnerships EVT Equity & BRIDGES Initiation of new BRIDGEs New operational
Slide 32: Upcoming important dates
Upcoming important dates Financial calendar 2021 Quarterly Statement Q1 2021 11 May 2021 Virtual Annual General Meeting 2021 15 June 2021 Half-year 2021 Interim Report 11 August 2021 Virtual Capital Markets Day Date tbc Quarterly Statement 9M 2021 11 November 2021 PAGE 31
Slide 33: Questions and Answers
Slide 34: Your contact: Dr Werner Lanthaler
Your contact: Dr Werner Lanthaler Chief Executive Officer +49.(0).40.560 81-242 +49.(0).40.560 81-333 Fax werner.lanthaler@evotec.com